Showing results (141-150 of 322) with videos related to

Sort By:
Pageof 33
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|March 21, 2006
Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast indurationSonja Brooker, Susan Martin, Ann Pearson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 10, 2005
Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapyLone Gothard, Paul Cornes, Sonja Brooker, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
European Urology|July 21, 2015
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisPiet Ost, Barbara Alicja Jereczek-Fossa, Nicholas Van As, et al.
BJU International|February 18, 2026
Characteristics and outcomes of men presenting with complications of metastatic prostate cancerArjun Nathan, Matthew G Parry, Adrian Cook, et al.
International Journal of Radiation Oncology, Biology, Physics|January 23, 2010
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis, Catherine M Corbishley, Karen Thomas, et al.
Clinical and Translational Radiation Oncology|March 7, 2023
Machine learning for normal tissue complication probability prediction: Predictive power with versatility and easy implementationPratik Samant, Dirk de Ruysscher, Frank Hoebers, et al.
Physics and Imaging in Radiation Oncology|November 10, 2021
Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancerJustine Tyler, David Bernstein, Matthew Seithel, et al.
Trials|January 8, 2026
Reviewing inclusivity of the UK bladder and head and neck oncology trial portfolio through eligibility criteria: a scoping reviewGeorgiana Synesi, Rebecca Lewis, Lucy Kilburn, et al.
Plos Genetics|February 28, 2009
Mutation of the mouse Syce1 gene disrupts synapsis and suggests a link between synaptonemal complex structural components and DNA repairEwelina Bolcun-Filas, Emma Hall, Robert Speed, et al.
Pageof 33